CIBORAT-OFTAN

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT CYBORAT-OPTHAN

Composition:

Active substances: zinc sulfate heptahydrate, boric acid;

1 ml of the preparation contains 2.5 mg of zinc sulfate heptahydrate, 20 mg of boric acid;

Excipient: purified water.

Pharmaceutical form. Eye drops.

Main physicochemical properties: clear, colorless liquid.

Pharmacotherapeutic group.

Agents used in ophthalmology. Antimicrobial agents. Zinc compounds.

ATC code S01A X03.

Pharmacological properties.

Pharmacodynamics.

The medicinal product exerts antimicrobial action locally against most gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.

The drug penetrates well through the conjunctival membrane, especially in children.

Pharmacokinetics.

Not studied.

Clinical characteristics.

Indications.

Bacterial etiology conjunctivitis.

Contraindications.

The use is contraindicated in case of increased sensitivity to the components of the drug, in case of renal or hepatic function impairment.

Interaction with other medicinal products and other forms of interactions.

Not established.

Special precautions for use.

Avoid prolonged use of the drug and exceeding the recommended doses, especially in children from 12 years of age.

With prolonged use of the drug (more than one month), symptoms of chronic intoxication may occur: local tissue edema, dizziness, stomatitis, eczema, menstrual cycle disturbances in women, anemia, myalgia, convulsions, fever, renal function impairment, electrolyte imbalance, dehydration.

In such cases, the drug should be discontinued and symptomatic treatment initiated.

In case of accidental ingestion, symptoms of acute poisoning may occur: nausea, vomiting, diarrhea, circulatory disturbances, central nervous system depression, decreased body temperature, respiratory disturbances, erythematous rash. In such cases, perform tube gastric lavage, administer orally saline laxatives, enterosorbents (activated charcoal), and symptomatic therapy. In case of severe poisoning, take measures to support vital functions and perform hemodialysis or peritoneal dialysis.

Use during pregnancy or breastfeeding.

The use of the medicinal product during pregnancy is contraindicated.

If treatment with the drug is necessary, breastfeeding should be discontinued.

Ability to influence reaction rate when driving or operating machinery.

Unknown.

Method of Administration and Dosage.

For adults and children aged 12 years and older, instill 2 drops of the preparation 2–3 times daily into each eye using a dropper. Treatment duration is 1–3 weeks.

Children.

Do not use in children under 12 years of age.

Overdose.

Overdose may occur with frequent use of the preparation (more than 3 times daily throughout the treatment course), manifesting as symptoms of chronic intoxication. Discontinuation of the preparation and symptomatic therapy are indicated.

Side effects.

Local allergic reactions, redness, itching, eyelid swelling, irritation, and eye pain may occur with local application.

With prolonged or frequent use, signs of systemic absorption may occur; systemic reactions include nausea, vomiting, diarrhea, dehydration, skin rashes, muscle pain, headache, and possible impairment of kidney and liver function, especially in children.

If any adverse effects occur, consult a doctor immediately!

Shelf life. 2 years.

Storage conditions.

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging.

10 ml in bottles.

Prescription status. Prescription only.

Manufacturer.

JSC "FITOPHARM".

Manufacturer's name and address.

84500, Sybirtseva St., 2, Bakhmut, Donetsk region, Ukraine.

Marketing Authorization Holder.

JSC "FITOPHARM".

Address of the Marketing Authorization Holder.

7, Verkhovnoi Rady Ave., Kyiv, 02100, Ukraine, floor 3, room 18.